Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00CCI
|
||||
| Former ID |
DCL000338
|
||||
| Drug Name |
Benoxaprofen
|
||||
| Synonyms |
Benoxaprofene; Benoxaprofeno; Benoxaprofenum; Coxigon; Inflamid; Opren; Oraflex; Uniprofen; LRCL3794; Lilly 90459; Benoxaprofene [INN-French]; Benoxaprofeno [INN-Spanish]; Benoxaprofenum [INN-Latin]; Dl-Benoxaprofen; Oraflex (TN); Benoxaprofen (USAN/INN); Benoxaprofen [USAN:INN:BAN]; (+-)-2-(p-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; (-)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; (-)-Benoxaprofen; (1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid; 2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid; 2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; 2-(p-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid; 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10:C11, C44, K75.9, M00-M25] | Withdrawn from market | [533566] | ||
| Company |
Eli Lilly
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H12ClNO3
|
||||
| Canonical SMILES |
CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O
|
||||
| InChI |
1S/C16H12ClNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20)
|
||||
| InChIKey |
MITFXPHMIHQXPI-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 51234-28-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
147908, 224775, 5305710, 8176323, 10524732, 12015308, 15023419, 17397235, 34705785, 46508496, 48415610, 49892019, 50154871, 57288750, 57312361, 103367920, 104333099, 117542968, 126666093, 126687083, 128601792, 134223756, 134338992, 135000902, 135127612, 137006826, 143201304, 160967788, 162635350, 164347369, 179150523, 223671949, 223678444, 225249486, 226412765, 249810602, 250102997, 251892107
|
||||
| SuperDrug ATC ID |
M01AE06
|
||||
| SuperDrug CAS ID |
cas=051234287
|
||||
| Target and Pathway | |||||
| Target(s) | Acetyl-CoA acetyltransferase, mitochondrial | Target Info | Inhibitor | [537712] | |
| KEGG Pathway | Fatty acid degradation | ||||
| Synthesis and degradation of ketone bodies | |||||
| Valine, leucine and isoleucine degradation | |||||
| Lysine degradation | |||||
| Tryptophan metabolism | |||||
| Pyruvate metabolism | |||||
| Glyoxylate and dicarboxylate metabolism | |||||
| Propanoate metabolism | |||||
| Butanoate metabolism | |||||
| Terpenoid backbone biosynthesis | |||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Carbon metabolism | |||||
| Fatty acid metabolism | |||||
| NetPath Pathway | Leptin Signaling Pathway | ||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.